Dataset Information

Metabolomic profiling of cerebrospinal fluid from dogs with meningoencephalitis of unknown origin by nuclear magnetic resonance

ABSTRACT:

Introduction: Meningoencephalitis of unknown origin (MUO) in dogs is a very debilitating and potentially fatal disease that is a potential model for multiple sclerosis in humans. The metabolomic profile of MUO has not been previously reported.

Objectives: To describe the metabolomic profile of the cerebrospinal fluid (CSF) of dogs with MUO and compare it with two different diseases affecting the central nervous system in dogs: steroid responsive meningitis-arteritis (SRMA) and idiopathic epilepsy (IE).

Methods: Untargeted metabolomics using 1H nuclear magnetic resonance (NMR) was performed on surplus CSF of dogs diagnosed with MUO, SRMA and IE. Data were examined by both multivariate and univariate statistical analysis and also pathway analysis.

Results: Fifty-six metabolites were identified and quantified. The multivariate analysis of the canine data highlighted significant differences between the different diseases groups. Most metabolites were increased in SRMA and decreased in IE when compared to MUO. Most affected metabolites included those involved in energy metabolism. Pathway analysis revealed that pyruvate metabolism, glycolysis or gluconeogenesis and glycine, serine and threonine metabolism were overrepresented in the CSF of patients with MUO compared to IE

Conclusion: These results suggest that there is an increased energy demand in MUO. Our findings provide a first-time overview of CSF metabolic changes in MUO and offer potential insights for possible underlying pathogenesis and treatment strategies.

INSTRUMENT(S): Nuclear Magnetic Resonance (NMR) -

PROVIDER: MTBLS6053 | MetaboLights | 2026-03-05

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	a_MTBLS6053_NMR___metabolite_profiling-1.txt	Txt
	a_MTBLS6053_NMR___metabolite_profiling.txt	Txt
	i_Investigation.txt	Txt
	m_MTBLS6053_NMR___metabolite_profiling-1_v2_maf.tsv	Tabular
	m_MTBLS6053_NMR___metabolite_profiling_v2_maf.tsv	Tabular

Items per page:

1 - 5 of 6

Publications

NMR metabolomic profiling of cerebrospinal fluid from dogs with meningoencephalitis of unknown origin demonstrates metabolic similarities to multiple sclerosis.

Gonçalves Rita R Walmsley Gemma G Maddox Thomas W TW Clarke Emily J EJ Phelan Marie M MM

Metabolomics : Official journal of the Metabolomic Society 20260209 2

<h4>Introduction</h4>Meningoencephalitis of unknown origin (MUO) in dogs is a debilitating and often fatal disease that shows similarities to multiple sclerosis (MS) in humans. The metabolomic profile of MUO has not been previously reported.<h4>Objectives</h4>To compare the metabolomic profile of cerebrospinal fluid (CSF) of dogs with MUO with two other diseases affecting the central nervous system in dogs, steroid responsive meningitis-arteritis (SRMA) and idiopathic epilepsy (IE), and to deter ...[more]

PMID: 41663848

Similar Datasets

Project description:Introduction: The relationship between epilepsy and cognitive dysfunction has been investigated in canines, and memory impairment was prevalent in dogs with epilepsy. There is some evidence that canines with epilepsy have greater amyloid-β (Aβ) accumulation and neuronal degeneration than healthy controls. The present study investigated plasma Aβ42 levels and performed proteomic profiling in dogs with refractory epilepsy and healthy dogs. Methods: In total, eight dogs, including four healthy dogs and four dogs with epilepsy, were included in the study. Blood samples were collected to analyze Aβ42 levels and perform proteomic profiling. Changes in the plasma proteomic profiles of dogs were determined by nano LC-MS/MS. Results and discussion: The plasma Aβ42 level was significantly higher in dogs with epilepsy (99 pg/mL) than in healthy dogs (5.9 pg/mL). In total, 155 proteins were identified, and of these, the expression of 40 proteins was altered in epilepsy. Among these proteins, which are linked to neurodegenerative diseases, 10 (25%) were downregulated in dogs with epilepsy, whereas 12 (30%) were upregulated. The expression of the acute phase proteins haptoglobin and α2-macroglobulin significantly differed between the groups. Complement factor H and ceruloplasmin were only detected in epilepsy dogs, suggesting that neuroinflammation plays a role in epileptic seizures. Gelsolin, which is involved in cellular processes and cytoskeletal organization, was only detected in healthy dogs. Gene Ontology annotation revealed that epilepsy can potentially interfere with biological processes, including cellular processes, localization, and responses to stimuli. Seizures compromised key molecular functions, including catalytic activity, molecular function regulation, and binding. Defense/immunity proteins were most significantly modified during the development of epilepsy. In Kyoto Encyclopedia of Genes and Genomes pathway analysis, complement and coagulation cascades were the most relevant signaling pathways affected by seizures. The findings suggested that haptoglobin, ceruloplasmin, α2-macroglobulin, complement factor H, and gelsolin play roles in canine epilepsy and Aβ levels based on proteomic profiling. These proteins could represent diagnostic biomarkers that, after clinical validation, could be used in veterinary practice as well as proteins relevant to disease response pathways. To determine the precise mechanisms underlying these relationships and their implications in canine epilepsy, additional research is required.